Cargando…
Recent developments in targeting access to high cost medicines in Australia
BACKGROUND: In Australia, the Pharmaceutical Benefits Scheme (PBS) has developed a set of arrangements to control access to high-cost medicines to ensure their use is cost-effective. These medicines include the tumour necrosis factor-alpha inhibitors (TNFIs) for the treatment of rheumatoid arthritis...
Autores principales: | Lu, Christine Y, Ritchie, Jan, Williams, Kenneth M, Day, Richard O |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1325248/ https://www.ncbi.nlm.nih.gov/pubmed/16305742 http://dx.doi.org/10.1186/1743-8462-2-28 |
Ejemplares similares
-
The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia
por: Lu, Christine Y, et al.
Publicado: (2007) -
Access to high cost medicines in Australia: ethical perspectives
por: Lu, Christine Y, et al.
Publicado: (2008) -
The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines
por: Lu, Christine Y, et al.
Publicado: (2007) -
From growers to patients: Multi-stakeholder views on the use of, and access to medicinal cannabis in Australia
por: Erku, Daniel, et al.
Publicado: (2022) -
Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis
por: Sruamsiri, Rosarin, et al.
Publicado: (2016)